View Older Stories View More Recent Stories

Jun 12, 2024 06:36AM Moderna (MRNA) PT Raised to $179 at Oppenheimer, 'mResvia is competitive as an RSV vaccine'

Jun 10, 2024 01:54PM Moderna (MRNA): expects to file for approval of RSV vaccine in adults aged 18 to 59 this year - Company executive at conference

Jun 10, 2024 11:28AM Midday movers: Southwest Airlines, CrowdStrike, KKR rise; AMD falls

Jun 10, 2024 08:58AM Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)

Jun 10, 2024 06:52AM Morgan Stanley Reiterates Equalweight Rating on Moderna (MRNA)

Jun 10, 2024 06:52AM Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'

Jun 10, 2024 06:30AM Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Jun 10, 2024 05:31AM Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

View More Recent Stories View Older Stories